These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42 related articles for article (PubMed ID: 24344159)
1. Prevalence of Raynaud phenomenon in the general population. A preliminary study by questionnaire. Maricq HR; Weinrich MC; Keil JE; LeRoy EC J Chronic Dis; 1986; 39(6):423-7. PubMed ID: 3711250 [TBL] [Abstract][Full Text] [Related]
2. Serum adhesion molecule levels as prognostic markers in patients with early systemic sclerosis: a multicentre, prospective, observational study. Hasegawa M; Asano Y; Endo H; Fujimoto M; Goto D; Ihn H; Inoue K; Ishikawa O; Kawaguchi Y; Kuwana M; Ogawa F; Takahashi H; Tanaka S; Sato S; Takehara K PLoS One; 2014; 9(2):e88150. PubMed ID: 24516598 [TBL] [Abstract][Full Text] [Related]
3. Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8/A9 as a novel possible marker for systemic sclerosis phenotype. van Bon L; Cossu M; Loof A; Gohar F; Wittkowski H; Vonk M; Roth J; van den Berg W; van Heerde W; Broen JC; Radstake TR Ann Rheum Dis; 2014 Aug; 73(8):1585-9. PubMed ID: 24718960 [TBL] [Abstract][Full Text] [Related]
4. Serum amyloid A is a marker for pulmonary involvement in systemic sclerosis. Lakota K; Carns M; Podlusky S; Mrak-Poljsak K; Hinchcliff M; Lee J; Tomsic M; Sodin-Semrl S; Varga J PLoS One; 2015; 10(1):e0110820. PubMed ID: 25629975 [TBL] [Abstract][Full Text] [Related]
5. New potential biomarkers for disease activity and fibrosis in systemic sclerosis. Vadasz Z; Rimar D Isr Med Assoc J; 2014 Oct; 16(10):629-30. PubMed ID: 25438451 [No Abstract] [Full Text] [Related]
6. Systemic sclerosis biomarkers discovered using mass-spectrometry-based proteomics: a systematic review. Bălănescu P; Lădaru A; Bălănescu E; Băicuş C; Dan GA Biomarkers; 2014 Aug; 19(5):345-55. PubMed ID: 24831309 [TBL] [Abstract][Full Text] [Related]
7. Caveolin-1 deficiency may predispose African Americans to systemic sclerosis-related interstitial lung disease. Reese C; Perry B; Heywood J; Bonner M; Visconti RP; Lee R; Hatfield CM; Silver RM; Hoffman S; Tourkina E Arthritis Rheumatol; 2014 Jul; 66(7):1909-19. PubMed ID: 24578173 [TBL] [Abstract][Full Text] [Related]
8. Brief report: lysyl oxidase is a potential biomarker of fibrosis in systemic sclerosis. Rimar D; Rosner I; Nov Y; Slobodin G; Rozenbaum M; Halasz K; Haj T; Jiries N; Kaly L; Boulman N; Daood R; Vadasz Z Arthritis Rheumatol; 2014 Mar; 66(3):726-30. PubMed ID: 24574233 [TBL] [Abstract][Full Text] [Related]
9. Association of Interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Christmann RB; Sampaio-Barros P; Stifano G; Borges CL; de Carvalho CR; Kairalla R; Parra ER; Spira A; Simms R; Capellozzi VL; Lafyatis R Arthritis Rheumatol; 2014 Mar; 66(3):714-25. PubMed ID: 24574232 [TBL] [Abstract][Full Text] [Related]
10. Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development. Lambrecht S; Smith V; De Wilde K; Coudenys J; Decuman S; Deforce D; De Keyser F; Elewaut D Arthritis Rheumatol; 2014 Feb; 66(2):418-27. PubMed ID: 24504814 [TBL] [Abstract][Full Text] [Related]
12. Current perspective on rituximab in rheumatic diseases. Schioppo T; Ingegnoli F Drug Des Devel Ther; 2017; 11():2891-2904. PubMed ID: 29042750 [TBL] [Abstract][Full Text] [Related]